Oriental Aromatics Q4 FY26: Revenue crosses INR 10,308 Mn, but margins stay under pressure

Oriental Aromatics ended FY26 with a clear top line milestone. Consolidated revenue from operations rose to INR 10,308 Mn, up 11.0 percent year on year, taking the company past the INR 1,000 crore annual revenue mark. In Q4 FY26, revenue grew to INR 2,824 Mn, up 11.5 percent year on year and 12.2 percent sequentially, supported by healthy demand across Specialty Aroma Ingredients, Flavour and Fragrance, and Camphor.

But FY26 also highlighted how quickly profitability can compress in a specialty chemicals and ingredients business when costs and operating leverage move the wrong way. Full year EBITDA fell to INR 680 Mn from INR 934 Mn in FY25, and EBITDA margin declined to 6.60 percent from 10.06 percent. Profit after tax dropped sharply to INR 32 Mn in FY26, with PAT margin at 0.31 percent. The contrast between volume growth and profit compression is the key thread in this year’s performance.

In the quarter, profitability looked more stable. Q4 FY26 EBITDA was INR 195 Mn, nearly flat year on year, while net profit rose to INR 40 Mn from INR 14 Mn in Q4 FY25. EBITDA margin in the quarter was 6.91 percent, down 71 bps year on year but up 166 bps sequentially. The sequential recovery mattered because Q3 FY26 had reported a loss, while Q4 returned to positive earnings.

A business built across ingredients, formulations, and camphor

Oriental Aromatics operates across aroma chemicals and camphor, and also formulations in flavours and fragrances. It is positioned as an integrated manufacturer that spans key parts of the value chain, from pine based and petrochemical based raw materials through to aroma ingredients, synthetic camphor, and customized fragrance and flavour products.

The company’s manufacturing footprint reflects this mix. Aroma chemicals and camphor facilities are located in Bareilly in Uttar Pradesh, Vadodara in Gujarat, and Mahad in Maharashtra. Flavours and fragrances manufacturing is located at Ambernath in Maharashtra. R and D is supported by a Centre for Innovation in Mumbai and a process re engineering lab in Vadodara, which is important in a portfolio where product mix shifts and process optimization can materially impact costs and realizations.

Geographically, FY26 sales were 67 percent domestic and 33 percent international. This split indicates a business that is still India led, but with meaningful export exposure, which can diversify demand but also adds sensitivity to global customer cycles and competitive intensity.

Q4 FY26: growth in sales volumes, lower production due to mix and trials

Operationally, Q4 FY26 showed strong demand and better sales volumes. Total sales volume grew 16 percent sequentially and 5 percent year on year. This is consistent with the revenue growth profile in the quarter and suggests the company was able to keep shipments moving across its divisions.

Production volumes moved differently. Total production volume in Q4 FY26 declined 7 percent sequentially and 14 percent year on year. Management attributed this to lower production in the Specialty Chemicals division due to product mix changes, along with trial runs and production of new product intermediates. This detail matters for investors because trial runs and new intermediates usually signal development work and pipeline progression, but they can also temporarily reduce throughput and affect absorption of fixed costs.

The quarterly income statement shows that higher revenues did not translate into higher EBITDA in the same proportion. Total operational income rose to INR 2,824 Mn, but total expenses increased to INR 2,629 Mn. EBITDA was INR 195 Mn versus INR 193 Mn in Q4 FY25. EBITDA margin eased to 6.91 percent from 7.62 percent. Depreciation rose to INR 77 Mn, and finance cost was INR 87 Mn.

Net profit improved in Q4 FY26 to INR 40 Mn, helped by a sharp rise in other income to INR 42 Mn versus INR 2 Mn in Q4 FY25. PBT nearly doubled to INR 73 Mn, and EPS for the quarter was INR 1.18.

FY26: revenue growth, but costs and financial charges compress earnings

At the full year level, FY26 was defined by revenue growth paired with weaker margins. Total operational income increased to INR 10,308 Mn from INR 9,283 Mn. But total expenses rose faster, to INR 9,628 Mn from INR 8,349 Mn. That cost growth translated into EBITDA declining to INR 680 Mn from INR 934 Mn.

Below EBITDA, fixed charges rose meaningfully. Depreciation increased to INR 311 Mn from INR 237 Mn, and finance cost increased to INR 358 Mn from INR 252 Mn. These two lines alone added material pressure versus FY25, and they explain why PBT fell to INR 107 Mn from INR 476 Mn even after higher other income of INR 96 Mn.

The outcome was a steep fall in PAT to INR 32 Mn, down from INR 343 Mn. PAT margin was 0.31 percent, and EPS for FY26 was INR 0.98. In effect, the company grew the top line but retained very little incremental profit, reflecting a challenging year for profitability.

Financial summary

Balance sheet and cash flows: leverage rises modestly, cash generation improves from a weak base

FY26 ended with net debt to equity at 0.58x, described as a comfortable leverage position. This ratio has increased over time, rising from 0.34x in FY23 to 0.58x in FY26, which aligns with the rise in finance costs visible in the income statement.

In consolidated balance sheet terms, short term borrowings increased to INR 3,472 Mn in FY26 from INR 2,782 Mn in FY25, while long term borrowings declined to INR 548 Mn from INR 738 Mn. Total equity was broadly stable, with share capital at INR 168 Mn and other equity at INR 6,477 Mn.

On the asset side, inventories rose to INR 3,802 Mn from INR 3,646 Mn, and trade receivables increased to INR 2,523 Mn from INR 1,884 Mn. This working capital build is important context for cash flows. CFO in FY26 was positive at INR 24 Mn, an improvement from CFO of negative INR 345 Mn in FY25, but still close to break even relative to the revenue scale. Free cash flow in FY26 was negative INR 92 Mn, improving from negative INR 1,208 Mn in FY25.

Management also highlighted cash profit for FY26 at INR 34 crore, which helps reconcile the very low accounting PAT with the underlying cash earnings profile.

What the operating indicators suggest about FY27 setup

The operational commentary points to two signals that matter for how investors frame FY27.

First, demand appears supportive. The company noted healthy demand across all key divisions in Q4 FY26 and sustained growth in FY26 sales volumes, with total sales volume up 9 percent over FY25.

Second, execution focus has to shift to throughput, mix, and cost discipline. Production volumes in FY26 rose 5 percent year on year, but the quarterly dip in Q4, driven by mix changes and trial runs, indicates the portfolio is still being optimized. If new intermediates and trial runs convert into higher value products, they can support realizations, but the income statement shows that margins have not yet stabilized at the FY25 level.

The gap between FY25 and FY26 EBITDA margins, 10.06 percent to 6.60 percent, is large. With depreciation and finance costs also rising, any recovery in earnings will likely require a combination of stronger gross margins, better fixed cost absorption, and better working capital conversion.

Investor view: scale achieved, profitability needs rebuilding

Oriental Aromatics has achieved scale, diversified itself across aroma ingredients, camphor, flavours, and fragrances, and retained a meaningful export franchise with one third of revenue coming from international markets in FY26. Q4 FY26 showed the business can still grow volumes and revenue and return to quarterly profitability.

But FY26 also showed how sensitive the model is to cost inflation, mix shifts, and financial charges. Revenue growth of 11 percent did not translate into profit growth, and PAT fell to INR 32 Mn. The rise in depreciation and finance costs makes the earnings profile more demanding. The balance sheet remains manageable at 0.58x net debt to equity, but leverage has moved up and working capital intensity appears higher.

The core takeaway from the FY26 presentation is straightforward. The company has crossed the INR 10,000 Mn revenue threshold and is still seeing healthy demand. The next leg depends on restoring margins and converting volume growth into durable cash flows. If product mix changes and new intermediates improve realizations and efficiency, the operating leverage can turn favorable again. Until then, investors will likely track two things most closely: EBITDA margin trend and working capital discipline.